HCM - Hutchmed gains as Ipsen-partnered lymphoma drug undergoes review in China
2024-07-05 13:41:36 ET
More onHutchmed, Ipsen S.A., etc.
- Ipsen expands collaboration agreement with Exelixis
- Ipsen gains accelerated approval for elafibranor for rare liver disease
- Seeking Alpha’s Quant Rating on Hutchison China MediTech
- Historical earnings data for Hutchison China MediTech
- Financial information for Hutchison China MediTech